Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
Stocks in this Quantisnow insightHealth Care
Historical context for CAI
Across the 20 sessions after earlier CAI headlines, the stock closed higher 14 times and lower 6 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CAI | SPY |
|---|---|---|---|
| Mar 16, 2026 | Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer | +5.0% | +1.0% |
| Mar 11, 2026 | Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting | +0.4% | -0.1% |
| Mar 9, 2026 | Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer | +2.2% | +0.9% |
| Feb 27, 2026 | /C O R R E C T I O N -- Caris Life Sciences/and 2 other headlines that session | +4.7% | -0.5% |
| Feb 24, 2026 | Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug | +3.2% | +0.7% |
| Feb 23, 2026 | Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference | -9.7% | -1.0% |
Quantisnow market dataNASDAQ
CAI
Caris Life Sciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2025
Get push alerts for CAI
Full CAI profile on Quantisnow Follow CAI and get a push notification the moment its next story breaks.